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Following publication of the original paper [1], the authors identified errors the
paper.
Under the heading Whole-Exome Sequencing Reveals The Mutational Landscape in
the results section, the following text has been updated. The updated text is displayed
in bold typeface.
In contrast to the relatively small number of recurrent mutations, EGFR-mutant tu-
mors had complex genomes by DNA copy number analysis (Fig. 2b). Significant focal
amplifications and deletions, identified by GISTIC2 35, were evident in regions with
known cancer genes, for example significant focal Cdkn2a deletions (GISTIC q-
value = 1.39 × 10− 5) were evident and EGFRvIII (in Col1a1 locus, GISTIC q-value =
0.017) was recurrently amplified. Significantly recurrent focal deletions were present in
a novel putative glioma driver Adgrl2 (GISTIC q-value = 2.19 × 10− 6, Additional File 4:
Table S3). Although focal deletions in Nlrp1b were present, recent evidence sug-
gests these represent a strain-specific germline variant rather than being onco-
genic [2]. Several of the most significantly mutated genes were also in regions with
frequent deletions, including Trp53, Tead2 and Uimc1, supporting putative tumor sup-
pressive roles (Fig. 3i).
The caption of Fig. 3 has also been updated. The correct caption is supplied below.
The updated text is displayed in bold typeface.
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Figure 3. Conditional PiggyBac transposon mutagenesis substitutes for genomic instabil-
ity in EGFRvIII-mutant gliomas. A. Mouse constructs for PiggyBac transposition. The
ATP1-S2 transposon line, with 20 copies per cell. Conditional PiggyBac transposase tar-
geted to Rosa26 (tissue-specific PiggyBac transposase, TSPB), SA = splice acceptor; SD =
splice donor; CAG =CAG promoter; SB = Sleeping Beauty; PB = PiggyBac inverted re-
peats; iPBase = insect version of the PiggyBac transposase. The transposon can activate
gene transcription if it inserts in the same orientation as the gene, usually in a 5′ position.
Gene inactivation can occur if the transposon inserts in the body of the gene as a conse-
quence of gene trapping which can occur in either orientation because of the presence of
two splice acceptors and bidirectional poly(A) (pA) sites. B. Outline of the experimental
design: quadruple transgenic mice conditionally activate EGFRvIII expression and Piggy-
Bac transposition in the central nervous system. Resultant tumors are examined molecu-
larly by whole-exome sequencing and mapping of transposon insertions. C. Histology of
EGFRvIII-PB tumors; although not statistically significant, a higher proportion of grade IV
brain tumors are observed compared with tumors lacking transposition. D. Immunostain-
ing profile of a typical grade III brain glioma from an EGFRvIII-PB mouse, showing strong
expression of neural stem and transit-amplifying cell markers. Scale bar corresponds to
2.8 mm for top panel, and 200 μm for all other panels. E. Representative karyotype of
EGFRvIII-only and EGFRvIII-PB brain tumors, showing polyploidy in the non-PB tumor.
F. Chromosomal aberrations in EGFRvIII-only and EGFRvIII-PB tumors (n = 3 and n = 5
tumors respectively; mean chromosomal aberrations 19 vs 6.4, p = 0.013, unpaired two-
tailed t-test; plots show mean +/− standard deviation). G. Copy number profile of EGFR-
vIII-PB tumors (n = 20) with focal amplifications and deletions in key genes highlighted.
H. Mutational profile of 20 EGFRvIII-PB brain and spinal tumors from whole-exome se-
quencing. I. Key genes identified in gliomas, either as significantly mutated from MuSiC
or copy number altered from GISTIC2, across all mouse brain and spinal tumors in both
cohorts (note Nlrp1b deletions are however a germline variant [2]); each column rep-
resent one tumor.
In addition, the authors identified an error in the author name of Yoon Ha Choi.
The incorrect author name is: Yoonha Choi
The correct author name is: Yoon Ha Choi
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